Iron Deficiency in Heart Failure: An Overview

Iron Deficiency in Heart Failure: An Overview

Iron deficiency is an extremely common comorbidity in patients with heart failure, affecting up to 50% of all ambulatory patients. It is associated with reduced exercise capacity and physical well-being and reduced quality of life. Cutoff values have been identified for diagnosing iron deficiency in...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:JACC. Heart failure 2019-01, Vol.7 (1), p.36-46
Hauptverfasser: von Haehling, Stephan, Ebner, Nicole, Evertz, Ruben, Ponikowski, Piotr, Anker, Stefan D
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 46
container_issue 1
container_start_page 36
container_title JACC. Heart failure
container_volume 7
creator von Haehling, Stephan
Ebner, Nicole
Evertz, Ruben
Ponikowski, Piotr
Anker, Stefan D
description Iron deficiency is an extremely common comorbidity in patients with heart failure, affecting up to 50% of all ambulatory patients. It is associated with reduced exercise capacity and physical well-being and reduced quality of life. Cutoff values have been identified for diagnosing iron deficiency in heart failure with reduced ejection fraction as serum ferritin, 
doi_str_mv 10.1016/j.jchf.2018.07.015
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_2157661818</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2157661818</sourcerecordid><originalsourceid>FETCH-LOGICAL-p211t-f498688dde259882dcef9896399f15f6eb20de170470e6e13f493e3fadbbc0a23</originalsourceid><addsrcrecordid>eNo1jz1PwzAURS0kRKvSP8CAMrIk-Nm188xWFUorVeoCc-Qkz8JRvnCaov57IlHucpdzrnQZewCeAAf9XCVV8eUSwQETniYc1A2bCwEyhhTTGVsOQ8WnoAJEvGMzyZWShss5i_eha6NXcr7w1BaXyLfRjmw4RVvr6zHQS7Ruo-OZwtnTzz27dbYeaHntBfvcvn1sdvHh-L7frA9xLwBOsVsZ1IhlSUIZRFEW5AwaLY1xoJymXPCSIOWrlJMmkJMgSTpb5nnBrZAL9vS324fue6ThlDV-KKiubUvdOGQCVKo1IOCEPl7RMW-ozPrgGxsu2f9F-QvnlVD_</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2157661818</pqid></control><display><type>article</type><title>Iron Deficiency in Heart Failure: An Overview</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>von Haehling, Stephan ; Ebner, Nicole ; Evertz, Ruben ; Ponikowski, Piotr ; Anker, Stefan D</creator><creatorcontrib>von Haehling, Stephan ; Ebner, Nicole ; Evertz, Ruben ; Ponikowski, Piotr ; Anker, Stefan D</creatorcontrib><description>Iron deficiency is an extremely common comorbidity in patients with heart failure, affecting up to 50% of all ambulatory patients. It is associated with reduced exercise capacity and physical well-being and reduced quality of life. Cutoff values have been identified for diagnosing iron deficiency in heart failure with reduced ejection fraction as serum ferritin, &lt;100 μg/l, or ferritin, 100 to 300 μg/l, with transferrin saturation of &lt;20%. Oral iron products have been shown to have little efficacy in heart failure, where the preference is intravenous iron products. Most clinical studies have been performed using ferric carboxymaltose with good efficacy in terms of improvements in 6-min walk test distance, peak oxygen consumption, quality of life, and improvements in New York Heart Association functional class. Data from meta-analyses also suggest beneficial effects for hospitalization rates for heart failure and reduction in cardiovascular mortality rates. A prospective trial to investigate effects on morbidity and mortality is currently ongoing. This paper highlights current knowledge of the pathophysiology of iron deficiency in heart failure, its prevalence and clinical impact, and its possible treatment options.</description><identifier>EISSN: 2213-1787</identifier><identifier>DOI: 10.1016/j.jchf.2018.07.015</identifier><identifier>PMID: 30553903</identifier><language>eng</language><publisher>United States</publisher><ispartof>JACC. Heart failure, 2019-01, Vol.7 (1), p.36-46</ispartof><rights>Copyright © 2019 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30553903$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>von Haehling, Stephan</creatorcontrib><creatorcontrib>Ebner, Nicole</creatorcontrib><creatorcontrib>Evertz, Ruben</creatorcontrib><creatorcontrib>Ponikowski, Piotr</creatorcontrib><creatorcontrib>Anker, Stefan D</creatorcontrib><title>Iron Deficiency in Heart Failure: An Overview</title><title>JACC. Heart failure</title><addtitle>JACC Heart Fail</addtitle><description>Iron deficiency is an extremely common comorbidity in patients with heart failure, affecting up to 50% of all ambulatory patients. It is associated with reduced exercise capacity and physical well-being and reduced quality of life. Cutoff values have been identified for diagnosing iron deficiency in heart failure with reduced ejection fraction as serum ferritin, &lt;100 μg/l, or ferritin, 100 to 300 μg/l, with transferrin saturation of &lt;20%. Oral iron products have been shown to have little efficacy in heart failure, where the preference is intravenous iron products. Most clinical studies have been performed using ferric carboxymaltose with good efficacy in terms of improvements in 6-min walk test distance, peak oxygen consumption, quality of life, and improvements in New York Heart Association functional class. Data from meta-analyses also suggest beneficial effects for hospitalization rates for heart failure and reduction in cardiovascular mortality rates. A prospective trial to investigate effects on morbidity and mortality is currently ongoing. This paper highlights current knowledge of the pathophysiology of iron deficiency in heart failure, its prevalence and clinical impact, and its possible treatment options.</description><issn>2213-1787</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNo1jz1PwzAURS0kRKvSP8CAMrIk-Nm188xWFUorVeoCc-Qkz8JRvnCaov57IlHucpdzrnQZewCeAAf9XCVV8eUSwQETniYc1A2bCwEyhhTTGVsOQ8WnoAJEvGMzyZWShss5i_eha6NXcr7w1BaXyLfRjmw4RVvr6zHQS7Ruo-OZwtnTzz27dbYeaHntBfvcvn1sdvHh-L7frA9xLwBOsVsZ1IhlSUIZRFEW5AwaLY1xoJymXPCSIOWrlJMmkJMgSTpb5nnBrZAL9vS324fue6ThlDV-KKiubUvdOGQCVKo1IOCEPl7RMW-ozPrgGxsu2f9F-QvnlVD_</recordid><startdate>201901</startdate><enddate>201901</enddate><creator>von Haehling, Stephan</creator><creator>Ebner, Nicole</creator><creator>Evertz, Ruben</creator><creator>Ponikowski, Piotr</creator><creator>Anker, Stefan D</creator><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>201901</creationdate><title>Iron Deficiency in Heart Failure: An Overview</title><author>von Haehling, Stephan ; Ebner, Nicole ; Evertz, Ruben ; Ponikowski, Piotr ; Anker, Stefan D</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p211t-f498688dde259882dcef9896399f15f6eb20de170470e6e13f493e3fadbbc0a23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>von Haehling, Stephan</creatorcontrib><creatorcontrib>Ebner, Nicole</creatorcontrib><creatorcontrib>Evertz, Ruben</creatorcontrib><creatorcontrib>Ponikowski, Piotr</creatorcontrib><creatorcontrib>Anker, Stefan D</creatorcontrib><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>JACC. Heart failure</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>von Haehling, Stephan</au><au>Ebner, Nicole</au><au>Evertz, Ruben</au><au>Ponikowski, Piotr</au><au>Anker, Stefan D</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Iron Deficiency in Heart Failure: An Overview</atitle><jtitle>JACC. Heart failure</jtitle><addtitle>JACC Heart Fail</addtitle><date>2019-01</date><risdate>2019</risdate><volume>7</volume><issue>1</issue><spage>36</spage><epage>46</epage><pages>36-46</pages><eissn>2213-1787</eissn><abstract>Iron deficiency is an extremely common comorbidity in patients with heart failure, affecting up to 50% of all ambulatory patients. It is associated with reduced exercise capacity and physical well-being and reduced quality of life. Cutoff values have been identified for diagnosing iron deficiency in heart failure with reduced ejection fraction as serum ferritin, &lt;100 μg/l, or ferritin, 100 to 300 μg/l, with transferrin saturation of &lt;20%. Oral iron products have been shown to have little efficacy in heart failure, where the preference is intravenous iron products. Most clinical studies have been performed using ferric carboxymaltose with good efficacy in terms of improvements in 6-min walk test distance, peak oxygen consumption, quality of life, and improvements in New York Heart Association functional class. Data from meta-analyses also suggest beneficial effects for hospitalization rates for heart failure and reduction in cardiovascular mortality rates. A prospective trial to investigate effects on morbidity and mortality is currently ongoing. This paper highlights current knowledge of the pathophysiology of iron deficiency in heart failure, its prevalence and clinical impact, and its possible treatment options.</abstract><cop>United States</cop><pmid>30553903</pmid><doi>10.1016/j.jchf.2018.07.015</doi><tpages>11</tpages></addata></record>
fulltext fulltext
identifier EISSN: 2213-1787
ispartof JACC. Heart failure, 2019-01, Vol.7 (1), p.36-46
issn 2213-1787
language eng
recordid cdi_proquest_miscellaneous_2157661818
source Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection
title Iron Deficiency in Heart Failure: An Overview
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T05%3A11%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Iron%20Deficiency%20in%20Heart%20Failure:%20An%20Overview&rft.jtitle=JACC.%20Heart%20failure&rft.au=von%20Haehling,%20Stephan&rft.date=2019-01&rft.volume=7&rft.issue=1&rft.spage=36&rft.epage=46&rft.pages=36-46&rft.eissn=2213-1787&rft_id=info:doi/10.1016/j.jchf.2018.07.015&rft_dat=%3Cproquest_pubme%3E2157661818%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2157661818&rft_id=info:pmid/30553903&rfr_iscdi=true